Table 2 Evaluation at baseline, 6 and 12 months of 38 patients with idiopathic inflammatory myopathies after rituximab therapy
From: Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
Baseline | 6 months | 12 months | Δ% (12 months vs. Baseline) | |
|---|---|---|---|---|
Prednisone dose (mg/day) | 18.8 (10.0–36.3) | 8.8 (2.5–15.0) | 6.3 (0.0–16.3) | – |
MMT-8 (0–80) | 68.5 (56.8–72.5) | 72.0 (67.0–78.0) | 74.0 (70.0–78.0) | + 11.3 |
HAQ (0.00–3.00) | 1.00 (0.50–1.51) | 0.63 (0.25–1.00) | 0.50 (0.03–1.16) | −53.0 |
Patient’s VAS (0–10 cm) | 5.0 (3.0–7.0) | 3.0 (1.0–5.0) | 2.0 (0.0–4.0) | − 57.0 |
Physician’s VAS (0–10 cm) | 5.0 (3.8–7.0) | 3.0 (1.0–4.3) | 2.0 (1.0–4.0) | −60.0 |
Creatine phosphokinase (U/L) | 429 (123–971) | 224 (83–527) | 254 (83–551) | −8.6 |
Aldolase (U/L) | 5.5 (4.0–10.6) | 3.9 (3.2–6.9) | 3.6 (3.2–7.0) | −29.0 |
Severe infections | – | 0 | 0 | – |
Adverse events | – | 0 | 2 (5.3) | – |
Neoplasia | – | 0 | 1 (2.6) | – |